The selective estrogen receptor modulator (SERM) tamoxifen 3a (Figure 1a) is effective for the treatment of ER+ breast cancer [13]; however, resistance is a clinical problem [26] together with a small increase in incidences of blood clots and endometrial cancers for postmenopausal women [27,28]. The gene discussed is ESR1; the disease is endometrial cancer.